Longitudinal effects of CGRP-targeting migraine therapies on blood pressure and body mass index: A 12-month retrospective analysis.

Researchers studied the effects of migraine therapies targeting CGRP on blood pressure and body mass index. CGRP is known to affect blood vessel function and metabolism. They compared patients using CGRP therapies like erenumab and fremanezumab with those not using these treatments. The study used health records from the Jefferson Headache Center between 2018 and 2025. Previous reports indicated that erenumab might raise blood pressure, leading to a label change by the FDA. However, there was limited long-term data on how different CGRP therapies affect blood pressure and weight. The researchers aimed to fill this gap by analyzing real-world data. Their findings could help patients and doctors understand the cardiovascular and metabolic effects of these migraine treatments over time. This research is essential for improving patient care and managing potential side effects effectively. Clinical relevance: This study highlights the need for monitoring blood pressure and weight in patients using CGRP-targeting migraine therapies.